

Aurealis Pharma to Present at Asia Biotech Invest 2015 Conference on May 21st 2015

Kuopio Finland, Basel Switzerland – May 4th 2015

Aurealis Pharma, a private biopharmaceutical company focused on chronic inflammation and oncology, announced today that CEO Juha Yrjänheikki and CSO Thomas Wirth will attend and present the company at Asia Biotech Invest 2015 Conference in Hong Kong. The presentation is scheduled to Thursday, May 21st, 2015 at 10-11 am.

Dr. Wirth stated, “We are pleased to attend and present in Asia Biotech Invest 2015 Conference. We anticipate that our multitherapy technology with new proof-of-concept data will create excitement and interest within the biotech investor audience.”

Aurealis Pharma is a Kuopio Finland and Basel Switzerland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to effectively, safely and economically modulate and re-educate the distorted host immune microenvironment to proper state in chronic inflammation and cancer. Company’s technology is based on safe food-grade lactic acid bacteria delivering and secreting multiple human therapeutic proteins in target tissue facilitating protein/antibody combination therapy in a single product.

Asia Biotech Invest, organized in partnership with AusBiotech, is a leading biotech investment conference in Asia gathering over 150 of the world’s leading biotech investors seeking new investment opportunities and biotech companies looking to raise capital. Asia Biotech Invest 2015 will be taking place at the Sheraton Hong Kong Hotel & Towers, May 19-21st 2015.

For more information:

Juha Yrjänheikki, CEO
Aurealis Pharma
Microkatu 1
FI-70210 Kuopio
Finland
Tel: +358 45 8433550
Email: juha(at)aurealispharma.com
www.aurealispharma.com



AUREALIS PHARMA
Microkatu 1
FI-70210 Kuopio
Finland

www.aurealispharma.com